Synergistic anticancer activity of Sulphoraphane and Teriflunomide co loaded lignin nanoparticles against triple negative breast cancer: Targeted nanoparticle delivery and drug repurposing
{"title":"Synergistic anticancer activity of Sulphoraphane and Teriflunomide co loaded lignin nanoparticles against triple negative breast cancer: Targeted nanoparticle delivery and drug repurposing","authors":"Debopriya Dutta , Lubna Siddiqui , Sadia Shah , Sushama Talegaonkar","doi":"10.1016/j.mehy.2024.111404","DOIUrl":null,"url":null,"abstract":"<div><p>Triple negative breast cancer stands out as the most aggressive subtype within the spectrum of breast malignancies, characterized by increased risks of recurrence, metastasis, and dismal prognosis. Notably, TNBC cells exhibit extensive overexpression of folate receptors, particularly folate receptor alpha, which drives tumor cell proliferation and migration. Addressing TNBC remains a formidable challenge in oncology, necessitating innovative therapeutic strategies. While chemotherapy serves as the cornerstone of TNBC treatment, its efficacy is often compromised by systemic toxicity, resulting in suboptimal clinical outcomes. This hypothesis proposes a novel approach utilizing lignin nanoparticles functionalized with folic acid for targeted delivery to FRα-overexpressing TNBC cells. These nanoparticles will encapsulate both the chemopreventive agent Sulphoraphane and the chemotherapeutic agent Teriflunomide, offering advantages such as enhanced drug targeting, synergistic therapeutic effects, cost-effectiveness, and reduced off-target toxicity. Additionally, this hypothesis highlights the repurposing of Teriflunomide to overcome drug resistance and the antioxidant properties of lignin. Furthermore, the ease of nanoparticle fabrication via self-assembly presents a promising avenue for streamlined production and clinical translation.</p></div>","PeriodicalId":18425,"journal":{"name":"Medical hypotheses","volume":"189 ","pages":"Article 111404"},"PeriodicalIF":2.1000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical hypotheses","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0306987724001476","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Triple negative breast cancer stands out as the most aggressive subtype within the spectrum of breast malignancies, characterized by increased risks of recurrence, metastasis, and dismal prognosis. Notably, TNBC cells exhibit extensive overexpression of folate receptors, particularly folate receptor alpha, which drives tumor cell proliferation and migration. Addressing TNBC remains a formidable challenge in oncology, necessitating innovative therapeutic strategies. While chemotherapy serves as the cornerstone of TNBC treatment, its efficacy is often compromised by systemic toxicity, resulting in suboptimal clinical outcomes. This hypothesis proposes a novel approach utilizing lignin nanoparticles functionalized with folic acid for targeted delivery to FRα-overexpressing TNBC cells. These nanoparticles will encapsulate both the chemopreventive agent Sulphoraphane and the chemotherapeutic agent Teriflunomide, offering advantages such as enhanced drug targeting, synergistic therapeutic effects, cost-effectiveness, and reduced off-target toxicity. Additionally, this hypothesis highlights the repurposing of Teriflunomide to overcome drug resistance and the antioxidant properties of lignin. Furthermore, the ease of nanoparticle fabrication via self-assembly presents a promising avenue for streamlined production and clinical translation.
期刊介绍:
Medical Hypotheses is a forum for ideas in medicine and related biomedical sciences. It will publish interesting and important theoretical papers that foster the diversity and debate upon which the scientific process thrives. The Aims and Scope of Medical Hypotheses are no different now from what was proposed by the founder of the journal, the late Dr David Horrobin. In his introduction to the first issue of the Journal, he asks ''what sorts of papers will be published in Medical Hypotheses? and goes on to answer ''Medical Hypotheses will publish papers which describe theories, ideas which have a great deal of observational support and some hypotheses where experimental support is yet fragmentary''. (Horrobin DF, 1975 Ideas in Biomedical Science: Reasons for the foundation of Medical Hypotheses. Medical Hypotheses Volume 1, Issue 1, January-February 1975, Pages 1-2.). Medical Hypotheses was therefore launched, and still exists today, to give novel, radical new ideas and speculations in medicine open-minded consideration, opening the field to radical hypotheses which would be rejected by most conventional journals. Papers in Medical Hypotheses take a standard scientific form in terms of style, structure and referencing. The journal therefore constitutes a bridge between cutting-edge theory and the mainstream of medical and scientific communication, which ideas must eventually enter if they are to be critiqued and tested against observations.